l e t t e r s
To identify susceptibility loci for classical Hodgkin's lymphoma (cHL), we conducted a genome-wide association study of 589 individuals with cHL (cases) and 5,199 controls with validation in four independent samples totaling 2,057 cases and 3,416 controls. We identified three new susceptibility loci at 2p16.1 (rs1432295, REL, odds ratio (OR) = 1.22, combined P = 1.91 × 10 −8 ), 8q24.21 (rs2019960, PVT1, OR = 1.33, combined P = 1.26 × 10 −13 ) and 10p14 (rs501764, GATA3, OR = 1.25, combined P = 7.05 × 10 −8 ). Furthermore, we confirmed the role of the major histocompatibility complex in disease etiology by revealing a strong human leukocyte antigen (HLA) association (rs6903608, OR = 1.70, combined P = 2.84 × 10 −50 ). These data provide new insight into the pathogenesis of cHL.
cHL is a lymph node cancer of germinal center B-cell origin characterized by malignant Hodgkin and Reed-Sternberg (HRS) cells mixed with a dominant background population of reactive lymphocytes and other inflammatory cells 1 . cHL is one of the most common tumors in young adults in economically developed countries, with ~1,500 cases being diagnosed each year in the UK, and the disease accounts for approximately one in three of all lymphomas 2, 3 . Although Epstein-Barr virus (EBV) infection may be causally related to a proportion of cases, the etiology of EBV-negative cHL remains largely unknown 4 .
Evidence for inherited genetic predisposition to cHL is provided by the three-to ninefold increased risk of cHL in first-degree relatives of individuals with cHL 5 . In the light of a possible viral basis for cHL, it is notable that cHL was the first disease to be associated with the HLA region 6 . Subsequent studies have reported associations between various HLA class I and class II alleles and risk of cHL 7, 8 , specifically, they reported an association between HLA-A*01 and HLA-A*02 for EBV-positive cHL 9, 10 . However, genetic variation in HLA is insufficient to account for the observed familial risk of cHL 11 .
A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24. 21 and 10p14 (GATA3) l e t t e r s To date, no non-HLA genetic risk factors have been identified and convincingly replicated. Genome-wide linkage studies of cHL families have failed to demonstrate an additional major gene locus for cHL 12 . This, coupled with the very high concordance of Hodgkin's lymphoma in monozygotic compared to dizygotic twins 13 , is consistent with a genetic model of inherited susceptibility based on the co-inheritance of multiple low-risk variants.
Predicated on this hypothesis, we conducted a genome-wide association study (GWAS) of 622 cHL cases from the UK using Illumina 660w-Quad BeadChips. Genotype frequencies were compared with publicly accessible genotype data generated by the UK Wellcome Trust Case-Control Consortium 2 (WTCCC2) study of 2,930 individuals from the 1958 British Birth Cohort (58C) 14 and 2,737 individuals from the UK Blood Service collections (UKBS) that had been genotyped using Illumina Human1.2M-Duo Custom_v1 Array BeadChips (Online Methods). There was no evidence of systematic bias between these two series (Online Methods and Supplementary Fig. 1 ), which were combined to provide genotype data for 5,667 controls. Data on 521,834 autosomal SNPs common to cases and controls were included in this analysis. After stringent quality control filtering (Online Methods and Supplementary Table 1) , we analyzed 504,374 SNPs in 589 cHL cases and 5,199 controls. Principal component analysis showed that these cases and controls were genetically well matched ( Supplementary Fig. 2 ). We therefore assessed the association between each SNP and cHL risk using the Cochran-Armitage trend test without principal component analysis adjustment. The quantile-quantile plots of the negative logarithm of genomewide P values showed a strong deviation from the null distribution ( Supplementary  Fig. 1 ), which could be ascribed to the strong association observed within the major histocompatibility complex (MHC) region. After excluding 1,700 SNPs mapping to the MHC region (6p21, at 28-33 Mb), there was only minimal inflation of the test statistics, except at the upper tail of the distribution (P < 10 −4 ), thereby rendering cryptic population substructure or differential genotype calling between cases and controls unlikely (genomic control inflation factor 15 (λ gc ) = 1.04; Supplementary  Fig. 1 ). Using principal components analyses as implemented in EIGENSTRAT 16 , a correction for possible population substructure had no influence on our findings for subsequently validated loci ( Table 1) . Furthermore, evidence for loci influencing cHL risk was provided by independent comparison with both 58C and UKBS control series ( Supplementary Table 2 ).
Our GWAS revealed multiple associations at chromosome 6, as well as suggestive associations on chromosomes 2, 5, 7, 8, 9, 10, 11 and 19 ( Fig. 1) . To validate these associations, we genotyped the HLA class II SNP rs6903608 and ten SNPs from other regions showing an association in the UK replication series (524 cases and 1,533 controls) (Online Methods and Supplementary Table 1 ). In the combined analysis, six of the SNPs were significantly associated at a combined P < 1.0 × 10 −4 ( Supplementary Table 3 ). These six SNPs were successfully genotyped in three independent case-control replication series (Online Methods and Supplementary Table 1 ): the Scandinavian Chr2
Chr18 Chr19 Figure 1 Genome-wide association results from the discovery phase. Shown are the genomewide P values obtained using the Cochran-Armitage trend test from 504,374 autosomal SNPs in 589 cHL cases and 5,199 controls. P values (-log 10 P, y axis) are plotted against their respective chromosomal positions (x axis). Each chromosome is depicted in a different color. The points with P < 10 −10 were truncated; the smallest P value obtained was 8.12 × 10 −21 . Table 1 and Supplementary Table 3 ).
In our GWAS, 42 SNPs mapping to the 4.8-Mb interval at 6p21 bordered by TRIM27 and MLN (rs209130 at 28,975,779 bp and rs1547668 at 33,883,424 bp, respectively), the genes defining the classical MHC region, showed evidence of an association with cHL risk at P < 5.0 × 10 −7 (Supplementary Fig. 3 ). The most significant associations were with SNPs mapping to HLA class II; the strongest signal was attained at rs6903608 centromeric to HLA-DRA (P = 8.12 × 10 −21 at 32,536,263 bp; Supplementary Fig. 3 ). The association between rs6903608 and cHL was consistently seen in each of the replication series at a combined P = 2.84 × 10 −50 ( Table 1 and Supplementary Table 3 ).
The association with rs1432295 (combined P = 1.91 × 10 −8 , OR = 1.22) on 2p16.1 (60,920,170 bp) straddles a recombination hotspot between two regions of high linkage disequilibrium (LD) ( Fig. 2 and Supplementary Fig. 4) . The 137-kb region defined by these two LD blocks encompasses the putative transcript FLJ16341 and REL (an avian reticuloendotheliosis viral oncogene homolog). REL encodes c-Rel, a member of the Rel/NFκB family of transcription factors. Constitutive activity of NFκB transcription factors is a hallmark of cHL 1 , and inactivating somatic mutations in genes encoding NFκB signaling inhibitors play a major role in cHL pathogenesis [18] [19] [20] . Furthermore, studies have shown genomic amplifications of REL to be associated with increased c-Rel expression in cHL [21] [22] [23] .
We identified two SNPs on 8q24.21 associated with cHL risk, rs2019960 (combined P = 1.26 × 10 −13 , OR = 1.33) and rs2608053 (combined P = 1.16 × 10 −7 , OR = 1.20). rs2608053, mapping at 129,145,014 bp, localizes to a 56-kb region of LD that encompasses intron 6 of PVT1 ( Fig. 2  and Supplementary Fig. 4 ). rs2019960, mapping at 129,261,453 bp, localizes to a 82-kb region of LD telomeric to PVT1 ( Fig. 2 and Supplementary Fig. 4 ). The effects of rs2019960 and rs2608053 on cHL risk are maintained when each is adjusted for the other by logistic regression (OR = 1.33, 95% CI 1.23-1.44, P = 1.97 × 10 −13 and OR = 1.20, 95% CI 1.12-1.28, P = 1.37 × 10 −7 , respectively). Furthermore, correlation between rs2019960 and rs2608053 is poor (r 2 = 0.0, D′ = 0.01 in HapMap European CEU samples and r 2 = 0.0, D′ = 0.03 in our control data), and comparison of haplotype frequencies provided evidence of two haplotypes differing in frequency between cases and controls (Supplementary Table 4 ). Because neither rs2019960 nor rs2608053 alone can fully account for the association between 8q24.21 and cHL, it is possible that a unique variant in LD with both SNPs and capturing the effects of both SNPs may exist. We did not, however, identify a more significant association in LD with both SNPs through imputation, making it plausible that two independent signals exist at 8q24.21.
PVT1 is frequently involved in translocations occurring in variant Burkitt's lymphoma and murine plasmacytomas 24 . The PVT1 locus encodes several microRNAs thought to be as important as MYC in T lymphomagenesis and T-cell activation 25 . Co-activation of c-Myc and PVT1 has been shown in a variety of human and animal tumors [26] [27] [28] . The 128-130 Mb genomic interval at 8q24.21 harbors multiple independent loci with different tumor specificities, including chronic lymphocytic leukemia (rs2456449 at 128,262,163 bp) 29 , as well as prostate (rs16901979 at 128,194,098 bp) 30 , breast (rs13281615 at 128,424,800 bp) 31 , colorectal and prostate (rs6983267 at 128,482,487 bp) 32, 33 , prostate (rs1447295 at 128,554,220 bp) 34 and bladder (rs9642880 at 128,787,250 bp) 35 cancer. The LD blocks defining these loci are distinct from the 8q24.21 cHL association signal (r 2 < 0.03; Supplementary Table 5 ). The colorectal cancer SNP rs6983267 shows differential binding of TCF4 to an enhancer element that physically interacts with the MYC promoter 36, 37 . A similar allelespecific cis effect either on MYC or through PVT1 affecting MYC expression provides an attractive mechanistic basis for the 8q24.21 l e t t e r s association with cHL risk. If the 8q24.21 locus influences risk through differential MYC expression, this association is intriguing because c-Myc and Rel/NFκB are the two master transcriptional systems activated in the latency III program of EBV-immortalized B cells, which are responsible for the phenotype, growth pattern and biological properties of cells driven into proliferation by EBV 38 .
The two SNPs showing an association with cHL mapping to 10p14, rs501764 (combined P = 7.05 × 10 −8 , OR = 1.25) and rs485411 (combined P = 1.29 × 10 −7 , OR = 1.22), are in strong LD (r 2 = 0.71, D′ = 0.95 in HapMap CEU samples and r 2 = 0.69, D′ = 1.00 in our control data) and map to a 40-kb region of LD encompassing the transcription factor and putative tumor suppressor gene GATA3 (encoding the GATA binding protein 3 isoform 2) ( Fig. 2 and Supplementary Fig. 4) . The expression of GATA3 is important in hematopoietic and lymphoid cell development, acting as a master transcription factor for differentiation of T h 2 cells 39 . A high proportion of the reactive infiltrate in cHL tumors is composed of T helper 2-like cells with a T regulatory phenotype, which can influence EBV-positive cHL cell growth, depending on EBV antigenic presentation by MHC molecules 40 . Notably, a key characteristic of HRS cells is the production of cytokines and chemokines driven by GATA3 expression and other T-cell transcription factors 41 . Evidence for a biological relationship between the 2p16.1, 8q24.21 and 10p14 loci is that members of the Rel family have differential effects on the MYC promoter 42 and that GATA3 is a target for c-Myc 43 .
Elucidation of the basis of each of the associations at 2p16.1, 8q24.21 and 10p14 will require fine mapping and functional analyses. To examine if any directly typed or imputed SNPs annotate a putative transcription-factor binding or enhancer element, we conducted a bioinformatic search of each of the regions of association using Transfac Matrix Database, PReMod and EEL software. At 10p14, an imputed SNP, rs369421, provided the best evidence for the association signal (P = 6.20 × 10 −7 ) and mapped within module 011553 ( Supplementary  Table 6 and Supplementary Fig. 4) . Notably, this module includes binding sites for ARID5B and E2F transcription factors. ARID5B has been previously implicated in development of acute leukemia 44 , and loss of PU.1, an E2F transcription factor, has been associated with defective immunoglobulin expression in HRS cells 45 .
A hallmark of cHL epidemiology is the bimodal age-specific incidence, and it has been argued that the disease in young adults and older adults are etiologically different; in particular, there is a low prevalence of EBV in younger cHL cases 46 . We assessed the relationship between cHL and EBV status, age and sex at the 6p21, 2p16.1, 8q24.21 and 10p14 loci (defined by rs6903608, rs1432295, rs2019960, rs2608053 and rs501764 genotypes) by a case-only analysis using data from SCALE, the UK and The Netherlands replication series (1,100 cases; Supplementary Table 7) . No associations at any of these loci were influenced by sex after adjustment for age and EBV status. The rs501764 association with cHL was not related to age or EBV status (Supplementary Table 7 ). The HLA class II association at 6p21 was primarily driven by EBV-negative cHL after adjustment for age and sex (adjusted P = 1.63 × 10 −11 ). Similarly, rs1432295 (2p16.1) risk alleles were significantly enriched in EBV-negative cHL (adjusted P = 0.01). At 8q24.21, whereas rs2608053 was associated with EBV-negative cHL (adjusted P = 0.01), rs2019960 showed a relationship with early onset cHL independent of EBV status or sex (adjusted P = 0.002) ( Supplementary Table 7 ). These phenotypic differences provide further support for two independent cHL risk loci at 8q24.21.
To explore whether any of the associations at 2p16.1, 8q24.21 and 10p14 reflect cis-acting regulatory effects on a nearby gene, we searched for genotype-expression correlations in 90 EBV-transformed lymphoblastoid cell lines using previously described data 47, 48 . We did not find any significant relationship between SNP genotype and gene expression after adjustment for multiple testing ( Supplementary  Fig. 5 ). This does not preclude the possibility that the causal variants at these disease loci have subtle effects on expression, as the dynamic range of transcripts such as MYC is small. Furthermore, it is likely that only a cumulative long-term imbalance in expression of target genes will influence cHL development, and expression differences may only be relevant to a specific subpopulation of B cells, which may not be well modeled by EBV-transformed lymphocytes.
Although the HLA association with cHL represents a very strong genetic effect, the identification of risk variants at 2p16.1, 8q24.21 and 10q14 implicates important roles for networks involving MYC, GATA3 and the NFκB pathway in cHL disease etiology. In the combined dataset, there was some evidence for interactions between HLA (rs6903608) and 2p16.1 (rs1432295, P = 0.05) and between 8q24.21 (rs2608053) and 10p14 (rs501764 and rs485411, P = 0.01), albeit these interactions were non-significant after correction for multiple testing ( Supplementary  Table 8 ). Further studies are needed to investigate possible interactions between these susceptibility loci and their interplay with EBV infection. Finally, the modest size of our study makes it likely that further risk variants for cHL can be identified through additional studies. 
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ONLINe MeTHOds
Genome-wide association study. We analyzed constitutional DNA from 622 cHL cases (defined according to the International Classification of Diseases (ICD) 10 codes C81.0-3) ascertained through the Royal Marsden Hospitals National Health Service Trust Family History study during 2004-2008 (n = 104, 63 male; mean age of diagnosis (AOD) = 38 years, standard deviation (s.d.) = 16 years) and an ongoing national study of cHL in females (n = 518, mean AOD = 23 years, s.d. = 6 years) conducted by the Institute of Cancer Research (ICR). One hundred forty-six cases had been diagnosed with breast cancer subsequent to cHL diagnosis. All cases were British residents and selfreported to be of European ancestry.
For controls, we used publicly accessible data generated by the UK Wellcome Trust Case Control Consortium 2 (WTCCC2) study on 5,667 individuals from two sources: 2,930 individuals from the British 1958 Birth Cohort (58C; also known as the National Child Development Study) 14 The Scandinavian Lymphoma Etiology (SCALE) study has been described previously 53, 54 . Briefly, SCALE is a population-based case-control study of Hodgkin's and non-Hodgkin's lymphomas conducted in Denmark and Sweden during 1999-2002. The study population encompassed Danish-or Swedishspeaking residents aged 18-74 years with no history of HIV infection, solid organ transplantation or previous hematopoietic malignancy in Denmark from June 1, 2000 to August 30, 2002 and in Sweden from October 1, 1999 to April 15, 2002 . Participants recruited in a Danish regional pilot phase starting November 1, 1999 were also included, as were prevalent cases of cHL diagnosed since January 1, 1999 in both countries. In total, 586 individuals diagnosed with cHL according to the World Health Organization classification in the study period and 3,187 controls, representing 91% and 71% of eligible cases and controls, respectively, participated in the study, which included a telephone interview and blood sampling. For the present investigation, DNA from 482 cases (82% of all SCALE cHL cases, 282 male, mean AOD = 40 years, s.d. = 16 years) and 255 Danish controls was extracted from dried filter paper blood spots with Extract-N-AmpT as per manufacturer's instructions (Sigma-Aldrich) and subjected to whole genome amplification with AmpliQ Genomic Amplifier Kit (Ampliqon) 55 . In addition, germline DNA extracted from buffy coat for 335 Danish SCALE controls (randomly selected from at total of 590 controls) was also included (mean age for combined SCALE controls = 59 years, s.d. = 13 years).
The Netherlands replication series comprised: (i) 281 cHL cases (149 male, mean AOD = 36 years, s.d. = 15 years) collected from the north of The Netherlands diagnosed during 1997-2000 as part of an ascertainment by the University Medical Centre Groningen; and (ii) 272 cHL cases, 97 diagnosed with breast cancer subsequent to cHL diagnosis (mean AOD = 24 years, s.d. = 6 years). These cases were selected in the framework of an ongoing case-control study of risk factors for breast cancer after Hodgkin's Lymphoma diagnosis conducted by the Netherlands Cancer Institute, Amsterdam, within a larger cohort study of women treated for cHL before age 60 during 1965-1995 and who survived at least 5 years after being diagnosed with cHL. Subject selection, methods of data, blood collection and DNA isolation have been described previously [56] [57] [58] . Samples from healthy blood donors aged 19-69 years ascertained through medical centers in Groningen (mean age = 52 years, s.d. = 11 years) and Leiden (mean age = 47 years, s.d. = 12 years) served as controls.
The German replication series comprised 498 cHL cases ascertained by the German Hodgkin Study Group during 1998-2007 (292 male, mean AOD = 34 years, s.d. = 12 years). The controls were 655 healthy blood donors from Mannheim, which is located 200 km from Cologne (381 male, mean age = 36 years, s.d. = 13 years).
EBV status of tumors. The EBV status of cHL tumors was determined by immunohistochemical staining for EBV latent membrane antigen (LMP)-1 and/or EBV EBV-encoded RNA (EBER) in situ hybridization using sections of paraffin-embedded material 53, 59 .
Ethics. Collection of blood samples and clinico-pathological information from subjects was undertaken with informed consent and relevant ethical review board approval in accordance with the tenets of the Declaration of Helsinki.
Genotyping. DNA was extracted from samples using conventional methodologies and quantified using PicoGreen (Invitrogen). Genotyping of cHL cases in the GWAS was conducted using Illumina Infinium HD Human660-Quad BeadChips according to the manufacturer's protocols (Illumina). DNA samples with GenCall scores <0.25 at any locus were considered 'no-calls' . A SNP was considered failed if fewer than 95% of DNA samples generated a genotype at the locus. Cluster plots were manually inspected for all SNPs considered for replication.
We used data on controls from the 1958 Birth Cohort (58C) and UK National Blood Service (UKBS) which was generated by the WTCCC. Genotyping of both sets of controls was conducted using Illumina Human 1.2M-Duo Custom_v1 Array chips. SNP calling was performed using Illuminus software. Full details of genotyping, SNP calling and quality control were reported previously (see URLs). Concordant with previous findings 17 , comparison of the two control series showed little evidence for systematic bias (inflation factor λ = 1.022; Supplementary Fig. 1) .
Validation and replication of associations were performed using competitive allele-specific PCR KASPar chemistry (KBiosciences Ltd). The primers and probes used are available on request. Samples with SNP call rates <90% were excluded from analysis. To ensure the quality of genotyping in all assays, at least two negative controls and 1%-2% duplicates (showing a concordance of >99.99%) were genotyped. We performed cross-platform validation and sequenced a random series of 96 samples to exclude technical artifacts and confirm genotyping accuracy (showing a concordance of >99.9%).
Statistical and bioinformatic analysis.
We applied predetermined qualitycontrol metrics to the GWAS data. We restricted analyses to samples for which >95% of SNPs were successfully genotyped, eliminating 12 cases. We computed identity-by-state (IBS) probabilities for all pairs to search for duplicates and closely related individuals among cases and controls (defined as IBS ≥0.80, thereby excluding first-degree relatives). For all identical pairs, the sample with highest call rate was retained, eliminating two cases. To identify individuals with possible non-western European ancestry, we merged our case and control data with samples from the HapMapII datasets (60 western European (CEU), 60 Nigerian (YRI), 90 Japanese (JPT) and 90 Han Chinese (CHB) individuals). For each pair of individuals, we calculated genome-wide IBS distances on markers shared between HapMap and our SNP panel, which we used as dissimilarity measures upon which to perform principal component analysis. The first two principal components for each individual were plotted; any individual not present in the main CEU cluster (that is, the 5% of individuals furthest from cluster centroids) was excluded. We removed 30 cases with non-CEU ancestry (some of which had poor call rates) and one WTCCC2 control which was a duplicate case. We excluded SNPs with minor allele frequency <1%, call rate <95% (cases or controls) and those showing departure from Hardy-Weinberg equilibrium (P < 10 −5 ) in controls. For replication and validation analysis, call rates were >95% per 384-well plate for each SNP; the cluster plots were visually examined by two researchers.
Main analyses were undertaken using R (v2.6), Stata10 (College Station, Texas, USA) and PLINK (v1.06). Association between each SNP and cHL risk was assessed by the Cochran-Armitage trend test. The adequacy of case-control matching and the possibility of differential genotyping of cases and controls were formally evaluated using quantile-quantile plots of test statistics. The inflation factor λ was based on the 90% least significant SNPs 15 . We adjusted for possible population substructure using EIGENSTRAT software 16 . ORs and associated 95% CIs were calculated using unconditional logistic regression. The meta-analysis was conducted using standard methods 60 . The Cochran's Q statistic and the I 2 statistic were calculated to test for heterogeneity and to quantify total variation due to heterogeneity; large heterogeneity is typically defined as I 2 ≥ 75% (ref. 61) . We conducted a pooled analysis incorporating EIGENSTRAT-adjusted P values from the GWAS using the weighted z method implemented in the program METAL. We examined each SNP for dose response by comparing 1-degree-of-freedom and 2-degree-of-freedom logistic regression models, adjusting for stage using a likelihood ratio test, and we examined the combined effects of multiple SNPs by evaluating the effect of adding an interaction term on the model by using a likelihood ratio test and adjusting for stage. Associations by sex, age and EBV status were examined by logistic regression in case-only analyses.
Prediction of the untyped SNPs was carried out using IMPUTEv2, based on HapMapIII Release27 (Feb2009, NCBI B36, dbSNP26) and the 1000 Genomes Project. Imputed data were analyzed using SNPTESTv2 to account for uncertainties in SNP prediction. LD metrics between HapMap SNPs were based on HapMapIII Release27, viewed using Haploview (v4.2) and plotted using SNAP. LD blocks were defined on the basis of HapMap recombination rate (cM/Mb) as defined using Oxford recombination hotspots 62 and on the basis of distribution of confidence intervals previously defined 63 . To annotate potential regulatory sequences within disease loci, we implemented in silico searches using Transfac Database(v7.29) 64 , PReMod10 65 and EEL 66 .
Relationships between SNP genotypes and expression levels.
To examine for a relationship between SNP genotype and expression levels of GATA3, REL and MYC in lymphocytes, we made use of publicly available expression data generated from analysis of 90 individuals of European descent derived Epstein-Barr virus-transformed lymphoblastoid cell lines using Sentrix Human-6 Expression BeadChips (Illumina) 47, 48 . Online recovery of data was performed using WGAViewer (v1.25). Differences in the distribution of mRNA expression levels between SNP genotypes were compared using a Wilcoxon-type trend test 67 .
